PRS30 Identifying the Patient Population Where Treatment of Severe Allergic Asthma with Omalizumab (XOLAIR®) Exhibits Optimal Cost-Effectiveness in Australia
Abstract
Authors
D. Tilden S. Cottrell L. Tocchini C. Frenzel M.A. Bonney